Clinical and demographic features of the patients enrolled (n = 29).

Clinical and demographic features of the patients enrolled (n = 29).</p

Concordance between different screening methods for latent TB infection at baseline.

Concordance between different screening methods for latent TB infection at baseline.</p

Comparison between the median values of INF-γ in response to the PHA mitogen of QFT-P before and after 3 and 12 months of therapy with Jaki.

PHA: phytohemagglutinin; QFT-P: QuantiFERON-TB Gold Plus; Jaki: Janus kinase inhibitors.</p

S1 File -

(XLSX)</p

Median INF-γ values in response to PHA mitogen after 3 months of baricitinib and tofacitinib treatment.

PHA: phytohemagglutinin.</p

QFT-P results according to the dose of glucocorticoids.

QFT-P: QuantiFERON-TB Gold Plus; PDN: prednisone.</p

IGRA results at baseline and after 3 and 12 months of treatment with Jaki.

IGRA results at baseline and after 3 and 12 months of treatment with Jaki.</p

Observational studies on tocilizumab efficacy in COVID-19 patients.

(DOCX)</p

Baseline characteristics of participants by treatment group.

Baseline characteristics of participants by treatment group.</p

Comparison between survivors and non-survivors for COVID-19-related death ^a,^b.

Comparison between survivors and non-survivors for COVID-19-related death a,b.</p